Across TCGA pan-cancer cohorts, NIPSNAP3A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NIPSNAP3A data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher NIPSNAP3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NIPSNAP3A expression acts as an unfavorable survival marker.
COAD, LUSC, and HNSC are the cancer types where NIPSNAP3A Mutation most reproducibly stratifies survival.